Search

Author/Creator Ackerman, Peter

2. 834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial. (4th December 2021)

Authors:
Chabria, Shiven; De Wit, Stephane; Pierce, Amy; Shepherd, Bronagh M; Warwick-Sanders, Michael; Du, Fangfang; Wang, Marcia; Clark, Andrew; Ackerman, Peter
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S509
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 834. Characterization of Heavily Treatment Experienced HIV-1 Infected Clinical Trial Participants Infected with SARS-CoV-2 COVID 19: Fostemsavir BRIGHTE Phase 3 Clinical Trial. (4th December 2021)

Authors:
Chabria, Shiven; De Wit, Stephane; Pierce, Amy; Shepherd, Bronagh M; Warwick-Sanders, Michael; Du, Fangfang; Wang, Marcia; Clark, Andrew; Ackerman, Peter
Journal:
Open forum infectious diseases
Issue:
Volume 8(2021)Supplement 1
Page Start:
S509
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. (1st June 2021)

Authors:
Ackerman, Peter; Thompson, Melanie; Molina, Jean-Michel; Aberg, Judith; Cassetti, Isabel; Kozal, Michael; Castagna, Antonella; Martins, Marcelo; Ramgopal, Moti; Sprinz, Eduardo; Treviño-Pérez, Sandra; Streinu-Cercel, Adrian; Latiff, Gulam H.; Pialoux, Gilles; Kumar, Princy N.; Wang, Marcia; Chabr...
Journal:
AIDS
Issue:
Volume 35:Number 7(2021)
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗